Hirson was hired in August this year as vice-president, development and operations, and has done an outstanding job of rebuilding the company's operations team, the company said.
Dr George Adams remains as chief executive.
Meanwhile, Dr Alvira Macanovic has been appointed manager of regulatory affairs and quality assurance at VentriPoint.
She has over 10 years' experience in pharmaceutical and medical device industries and worked with researchers, start-ups, SMEs and multinationals to commercialize technologies in multiple therapeutic areas.
The firm's device can analyse all four chambers of the heart using data from a conventional 2D (two dimensional) eco-cardiogram (in other words an ultrasound test).
This year the group reconfigured its VMS machine to accommodate newer ultrasound devices and provide a better form for clinical use.
The VMS+ machine needed to be recertified under ISO60601 specifications for safe medical devices. Testing program is now complete, and the company is awaiting a certificate.
Ventripoint also noted today it has moved its development and manufacturing centre, as well as its corporate offices, to 2 Sheppard Ave, East, suite 605, Toronto, Ontario.
Shares added 4% to C$0.26 on the day.